News

Rest assured, we are monitoring and successfully mitigating potential challenges due to ongoing supply chain disruptions to deliver material consistently to our customers. Learn more.

Promega's Cookie Policy

We use cookies and similar technologies to make our website work, run analytics, improve our website, and show you personalized content and advertising. Some of these cookies are essential for our website to work. For others, we won’t set them unless you accept them. To find out more about cookies and how to manage cookies, read our Cookie Policy.

Citations Search

Sort By:

MAbs 10(3), 370-379. Development and characterization of an anti-rituximab monoclonal antibody panel.

  2018

Tada, M., Suzuki, T., and Ishii-Watabe, A.

 

Notes: These authors used the CytoTox®-Glo Assay as the readout for a CDC assay, and the ADCC reporter bioassay, to evaluate the potency of anti-rituximab antibodies. 

  (5007)

Expand Full Notes »

J. Biol. Chem. 291(53), 27134–46. Fc engineering approaches to enhance the agonism and effector functions of an anti-OX40 antibody. 2016

Zhang, D., Goldberg, M. V. and Chiu, M. L.

Notes: Agonist antibodies targeting T cells and other immune cells to simulate immune activation have shown to be promising for cancer therapeutics. Here, the NanoBRET™ Protein-Protein Interaction Assay was used to measure hexamerization of anti-OX40 antibodies on the cell surface. Specific anti-OX40 antibody mutations were analyzed for increased antibody multimerization and engagement. Mutations promoting IgG hexamerization showed enhanced agonistic activity. (5056)

Expand Full Notes »